Sudden Death Associated with Substance Use

项目总结 心脏骤停(SCA)是一种突然的灾难性的脉搏丧失，仍然是一种主要的公共卫生问题 问题。SCA事件的一部分发生在吸毒者中，并考虑到药物过量 美国死亡人数达到前所未有的水平，与毒品相关的SCA的流行病学正在发生变化 迅速地。识别和描述与药物相关的SCA事件对于准确估计 与药物使用有关的死亡率，并向公共卫生措施提供信息，特别是在 持续的阿片类药物流行。这项拟议的研究将解决几个主要的知识差距。这个K01 职业发展奖利用两个正在进行的基础设施和临床数据归档 SCA的前瞻性社区研究。诺比博士将利用这些数据来检查猪流感的流行病学 与药物使用有关的SCA，总体目标是改进基于社区的SCA方法 预防。这项建议的目的是：1)找出机会，以提高SCA在 药物使用环境，以及2)确定在药物使用存在的情况下启动SCA的底物触发因素。 综合起来，这些目标将结合以社区为基础的监视和全面的调查 填补与物质使用有关的SCA事件的流行病学和研究空白的报告。致信地址 这些研究的目的是，诺比博士将在这两个社区收集SCA病例的记录和报告 之前因吸毒证据而被排除在外的人。此K01的总体目标是告知 一系列R系列拨款，以进一步研究SCA的预测和预防，并改进 与药物使用有关的SCA事件后的存活率。在这个K01奖项的支持下，诺比博士将能够 为了实现这一目标并通过基本培训和过渡到独立调查员的地位 师徒关系。她将接受1)跨系统组合多模式健康记录的高级培训 和提取相关信息；2)药物不良反应药物使用研究与分析 组合；以及3)SCA机制、SCA响应和护理，并另外熟悉 毒理学和尸检报告。锡达斯-西奈施密特心脏研究所提供理想的基础设施 完成研修培训活动。通过建议的研究、培训和职业生涯 发展诺比博士将获得必要的科学和专业技能，成为一名成功的 独立研究人员并领导一个研究项目，推动与药物相关的SCA领域 使用。

PROJECT SUMMARY Sudden cardiac arrest (SCA), a sudden catastrophic loss of the pulse, continues to be a major public health issue. A proportion of SCA events occur in persons engaging in drug use and given that drug overdose deaths are at unprecedented levels in the United States, the epidemiology of drug related SCA is changing rapidly. Recognition and characterization of drug related SCA events is critical for accurate estimates of mortality associated with drug use, and to inform public health measures, especially in the context of the ongoing opioid epidemic. This proposed study will address several of the major knowledge gaps. This K01 Career Development Award leverages the existing infrastructure and clinical data archive of two ongoing prospective community-based studies of SCA. Dr. Norby will use this data to examine the epidemiology of SCA associated with drug use, with the overall goal of improving community-based approaches to SCA prevention. This proposal aims to 1) identify opportunities that will improve survival from SCA in the setting of drug use, and 2) identify substrate-trigger factors that initiate SCA in the presence of drug use. Taken together, these aims will interface community-based surveillance and comprehensive investigative reports to fill in the epidemiology and research gaps in SCA events related to substance use. To address these research aims, Dr. Norby will assemble records and reports in these two communities for SCA cases that have previously been excluded due to evidence of drug use. The overall goal of this K01 is to inform a sequence of R series grants to further investigate the prediction and prevention of SCA, and to improve survival after an SCA event related to drug use. With the support of this K01 award, Dr. Norby will be able to pursue this goal and transition to independent investigator status through essential training and mentorship. She will gain advanced training in 1) combining multimodal health records across systems and extracting pertinent information; 2) pharmacoepi drug use research and analysis of drug-drug combination; and 3) SCA mechanisms, SCA response and care, and additionally gain familiarity with toxicology and autopsy reports. Cedars-Sinai Smidt Heart Institute provides the ideal infrastructure to complete the research and training activities. Through the proposed research, training, and career development Dr. Norby will gain the scientific and professional skills necessary to become a successful independent investigator and lead a research program that advances the field of SCA associated with drug use.